Galen Partners III L P
Galen Partners III L P
Galen Partners III L P insider trades: Acura Pharmaceuticals (ACUR) stock sales
Acura Pharmaceuticals Last trade Dec 14, 2017 45 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
78
Open-market trades
since 2008
5
Companies
last trade 2017
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Galen Partners III L P reports to the SEC
ACURAcura Pharmaceuticals
Insider · last filing Jan 2, 2018
-$5.4M
MDASMedassets
10% Owner · last filing May 19, 2010
-$19.4M
SHPISpecialized Health Products International
10% Owner · last filing Jun 10, 2008
-$15.4M
DSCIDerma Sciences
10% Owner · last filing May 11, 2007
No market trades
ENMCEncore Medical
10% Owner · last filing Nov 15, 2006
No market trades
Open-market buys and sales
78 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 14, 2017 | ACUR | ↓ Sell | 2,195,734 | $0.10 | $220K | Indirect | Jan 2, 2018 (19d) |
| Jun 17, 2015 | ACUR | ↓ Sell | 104,823 | $1.08 | $114K | See FN | Jun 18, 2015 (1d) |
| Jan 12, 2015 | ACUR | ↓ Sell | 171,000 | $0.62 | $106K | See FN | Jan 12, 2015 (0d) |
| Mar 3, 2014 | ACUR | ↓ Sell | 2,500 | $2.00 | $5K | See FN | Mar 5, 2014 (2d) |
| Feb 28, 2014 | ACUR | ↓ Sell | 351,260 | $2.02 | $711K | See FN | Feb 28, 2014 (0d) |
| Feb 24, 2014 | ACUR | ↓ Sell | 44,019 | $1.97 | $87K | See FN | Feb 25, 2014 (1d) |
| Feb 18, 2014 | ACUR | ↓ Sell | 2,200 | $1.95 | $4K | See FN | Feb 20, 2014 (2d) |
| Oct 10, 2013 | ACUR | ↓ Sell | 4,200 | $2.05 | $9K | See FN | Oct 11, 2013 (1d) |
| Jul 2, 2013 | ACUR | ↓ Sell | 200,000 | $2.15 | $430K | See FN | Jul 3, 2013 (1d) |
| Jun 17, 2013 | ACUR | ↓ Sell | 20,446 | $2.15 | $44K | See FN | Jun 19, 2013 (2d) |
| Jun 14, 2013 | ACUR | ↓ Sell | 31,283 | $2.16 | $67K | See FN | Jun 14, 2013 (0d) |
| Jun 10, 2013 | ACUR | ↓ Sell | 21,496 | $2.20 | $47K | See FN | Jun 11, 2013 (1d) |
| Jun 6, 2013 | ACUR | ↓ Sell | 39,453 | $2.19 | $86K | See FN | Jun 7, 2013 (1d) |
| May 31, 2013 | ACUR | ↓ Sell | 31,559 | $2.25 | $71K | See FN | Jun 3, 2013 (3d) |
| May 21, 2013 | ACUR | ↓ Sell | 47,410 | $2.30 | $109K | See FN | May 23, 2013 (2d) |
| May 20, 2013 | ACUR | ↓ Sell | 166,052 | $2.33 | $388K | See FN | May 20, 2013 (0d) |
| May 15, 2013 | ACUR | ↓ Sell | 183,434 | $2.33 | $427K | See FN | May 15, 2013 (0d) |
| May 7, 2013 | ACUR | ↓ Sell | 153,304 | $2.16 | $331K | See FN | May 7, 2013 (0d) |
| May 2, 2013 | ACUR | ↓ Sell | 174,758 | $2.41 | $422K | See FN | May 2, 2013 (0d) |
| Apr 29, 2013 | ACUR | ↓ Sell | 56,342 | $2.59 | $146K | See FN | Apr 29, 2013 (0d) |
| Apr 17, 2013 | ACUR | ↓ Sell | 238,756 | $3.20 | $765K | See FN | Apr 19, 2013 (2d) |
| Apr 16, 2013 | ACUR | ↓ Sell | 39,303 | $2.14 | $84K | See FN | Apr 16, 2013 (0d) |
| Apr 11, 2013 | ACUR | ↓ Sell | 121,454 | $2.23 | $270K | See FN | Apr 11, 2013 (0d) |
| Apr 9, 2013 | ACUR | ↓ Sell | 200,487 | $2.16 | $432K | See FN | Apr 9, 2013 (0d) |
| May 18, 2010 | MDAS | ↓ Sell | 30,856 | $24.11 | $744K | See FN | May 19, 2010 (1d) |
| Apr 26, 2010 | MDAS | ↓ Sell | 111,708 | $22.24 | $2.5M | See FN | Apr 26, 2010 (0d) |
| Mar 23, 2010 | MDAS | ↓ Sell | 42,373 | $22.13 | $938K | See FN | Mar 23, 2010 (0d) |
| Mar 18, 2010 | MDAS | ↓ Sell | 8,818 | $22.06 | $195K | See FN | Mar 18, 2010 (0d) |
| Nov 2, 2009 | MDAS | ↓ Sell | 55,584 | $22.11 | $1.2M | Indirect | Nov 3, 2009 (1d) |
| Oct 8, 2009 | MDAS | ↓ Sell | 15,199 | $22.06 | $335K | Indirect | Oct 13, 2009 (5d) |
| Oct 6, 2009 | MDAS | ↓ Sell | 10,047 | $22.06 | $222K | Indirect | Oct 7, 2009 (1d) |
| Oct 2, 2009 | MDAS | ↓ Sell | 30,608 | $22.12 | $677K | Indirect | Oct 5, 2009 (3d) |
| Sep 15, 2009 | MDAS | ↓ Sell | 55,854 | $22.19 | $1.2M | Indirect | Sep 17, 2009 (2d) |
| Aug 3, 2009 | MDAS | ↓ Sell | 41,346 | $19.00 | $786K | By Galen Partners III, L.P. | Aug 5, 2009 (2d) |
| Aug 3, 2009 | MDAS | ↓ Sell | 9,824 | $19.00 | $187K | By Galen Partners IV, L.P. | Aug 5, 2009 (2d) |
| Aug 3, 2009 | MDAS | ↓ Sell | 3,747 | $19.00 | $71K | By Galen Partners International III, L.P | Aug 5, 2009 (2d) |
| Aug 3, 2009 | MDAS | ↓ Sell | 780 | $19.00 | $15K | By Galen Partners International IV, L.P. | Aug 5, 2009 (2d) |
| Aug 3, 2009 | MDAS | ↓ Sell | 142 | $19.00 | $3K | By Galen Employee Fund III, L.P. | Aug 5, 2009 (2d) |
| Aug 3, 2009 | MDAS | ↓ Sell | 11 | $19.00 | $209 | By Galen Employee Fund IV, L.P. | Aug 5, 2009 (2d) |
| Jul 1, 2009 | MDAS | ↓ Sell | 41,346 | $19.16 | $792K | By Galen Partners III, L.P. | Jul 2, 2009 (1d) |
| Jul 1, 2009 | MDAS | ↓ Sell | 9,825 | $19.16 | $188K | By Galen Partners IV, L.P. | Jul 2, 2009 (1d) |
| Jul 1, 2009 | MDAS | ↓ Sell | 3,747 | $19.16 | $72K | By Galen Partners International III, L.P | Jul 2, 2009 (1d) |
| Jul 1, 2009 | MDAS | ↓ Sell | 780 | $19.16 | $15K | By Galen Partners International IV, L.P. | Jul 2, 2009 (1d) |
| Jul 1, 2009 | MDAS | ↓ Sell | 142 | $19.16 | $3K | By Galen Employee Fund III, L.P. | Jul 2, 2009 (1d) |
| Jul 1, 2009 | MDAS | ↓ Sell | 14 | $19.16 | $268 | By Galen Employee Fund IV, L.P. | Jul 2, 2009 (1d) |
| Jun 10, 2009 | MDAS | ↓ Sell | 41,346 | $17.06 | $705K | By Galen Partners III, L.P. | Jun 17, 2009 (7d) |
| Jun 10, 2009 | MDAS | ↓ Sell | 9,825 | $17.06 | $168K | By Galen Partners IV, L.P. | Jun 17, 2009 (7d) |
| Jun 10, 2009 | MDAS | ↓ Sell | 3,747 | $17.06 | $64K | By Galen Partners International III, L.P | Jun 17, 2009 (7d) |
| Jun 10, 2009 | MDAS | ↓ Sell | 780 | $17.06 | $13K | By Galen Partners International IV, L.P. | Jun 17, 2009 (7d) |
| Jun 10, 2009 | MDAS | ↓ Sell | 142 | $17.06 | $2K | By Galen Employee Fund III, L.P. | Jun 17, 2009 (7d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Galen Partners III L P's insider trades
Galen Partners III L P is an insider at Acura Pharmaceuticals (ACUR). Since Jun 6, 2008, it has reported no open-market purchases and 78 sales worth $40.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include other transactions (5 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACUR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.